Role of NT-proANP and NT-proBNP in patients with atrial fibrillation: Association with atrial fibrillation progression phenotypes.

BACKGROUND

Electroanatomic remodeling in atrial fibrillation (AF) leads to disease initiation and perpetuation. Although atrial natriuretic peptide (ANP) is specifically expressed in the atria and is involved in atrial remodeling, B-type natriuretic peptide (BNP) is associated with mortality and cardiovascular events in AF.

OBJECTIVE

The purpose of this study was to investigate the association between N-terminal (NT)-proBNP and NT-proANP levels with 3 AF progression phenotypes: persistent AF, left atrial diameter (LAD) dilation, and left atrial low-voltage areas (LVAs).

METHODS

We studied NT-proBNP and NT-proANP in a discovery cohort (n = 51) and replicated the findings in a validation cohort (n = 241) undergoing first AF catheter ablation. Blood plasma samples from femoral vein were collected before catheter ablation. LVAs were determined using high-density maps and defined as <0.5 mV.

RESULTS

In our pilot cohort (age 62 ± 10 years; 63% male; 59% persistent AF; 22% LVA), NT-proANP-but not NT-proBNP-levels were significantly higher in LVA patients (14.1 vs 8.6 ng/mL; P = .009) and correlated with LAD (r2 = 0.362; P = .011). These results were replicated in the validation cohort (age 64 ± 11 years; 59% male; 59% persistent AF; 27% LVA) (12.7 vs 8.8 ng/mL; P = .016) and correlated with LAD (r2 = 0.180; P = .019). NT-proANP levels increased according to 4 disease progression groups: paroxysmal AF without LVA, persistent AF without LVA, paroxysmal AF with LVA, and persistent AF with LVA (mean 15, 20, 19, and 27 ng/mL, respectively; P = .004).

CONCLUSION

Natriuretic peptides show different sensitivity for phenotypes of AF progression. The clinical impact of NT-proANP in refining individualized therapy and disease prevention should be addressed in larger studies.